ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Peptide Receptor-Functionalized AuNP-Embedded Zwitterionic Biopolymeric Nanohydrogel for Electrochemical Sclerostin Sensing.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sclerostin (SOST) is a key negative regulator of bone formation and an emerging biomarker associated not only with osteoporosis but also with chronic kidney disease. Despite its growing clinical relevance, biosensing platforms for SOST remain limited, with most existing approaches relying on antibody- or aptamer-based assays that often suffer from high cost, limited stability, and reduced performance in complex biological samples. Here, we report a peptide-based electrochemical biosensing platform enabled by a multifunctional zwitterionic biopolymeric nanohydrogel, composed of chitosan, carboxybetaine methacrylate, and gold nanoparticles (CS-ZI-AuNPs). This nanohydrogel acts as a unified antifouling biointerface, simultaneously providing resistance to nonspecific adsorption, stable peptide receptor immobilization, and efficient electrochemical signal transduction. The resulting biosensor achieves picomolar sensitivity with a detection limit of approximately 26.4 pg/mL, enabling accurate quantification of SOST across clinically relevant concentration ranges. Importantly, the platform demonstrates statistically significant discrimination between healthy individuals and patients with osteoporosis, postmenopausal osteoporosis, and chronic kidney disease (stages 1 and 3) using real clinical samples. By integrating zwitterionic antifouling chemistry with peptide-driven molecular recognition in a conductive nanostructured matrix, this work establishes a generalizable design principle for electrochemical biosensors targeting protein biomarkers. The proposed strategy offers a robust and scalable alternative to conventional immunoassays, with broad implications for translational diagnostics and real-time disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.